LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
37 hedge funds and large institutions have $165M invested in LogicBio Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
33% more capital invested
Capital invested by funds: $124M → $165M (+$40.8M)
12% more funds holding
Funds holding: 33 → 37 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.18M |
| 2 |
BlackRock
New York
|
+$1.13M |
| 3 |
State Street
Boston,
Massachusetts
|
+$683K |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$534K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$389K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.13M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.26M |
| 3 |
SCM
Sio Capital Management
New York
|
-$351K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$48.9K |
| 5 |
Morgan Stanley
New York
|
-$18.7K |
LOGC Hedge Fund Activity: Q2 2019 in Review
37 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q2 2019, worth a combined $165M — up 33% from $124M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LOGC positions and 1 closed out — a net gain of 5 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $5.18M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $4.13M sold.
- 37 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q2 2019, up from 33 in Q1 2019.
- Funds reported $165M of LogicBio Therapeutics, Inc. Common Stock stock for Q2 2019, up 33% quarter-over-quarter.
- 6 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q2 2019 and 1 closed out, a net change of +5 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q2 2019 was Adage Capital Partners, an estimated $5.18M added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q2 2019 was Sphera Funds Management, an estimated $4.13M sold.
Based on aggregated 13F filings for Q2 2019.